Prevalence, incidence, and outcomes of hepatitis E virus coinfection in patients with chronic hepatitis C.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
21 08 2023
21 08 2023
Historique:
received:
21
04
2023
accepted:
18
07
2023
medline:
23
8
2023
pubmed:
22
8
2023
entrez:
21
8
2023
Statut:
epublish
Résumé
This study aimed to elucidate the anti-hepatitis E virus (HEV) immunoglobulin G (IgG) prevalence and incidence of seroconversion and seroreversion as well as its risk factors and to analyze the clinical outcomes of HEV and hepatitis C virus (HCV) coinfected patients compared to those of HCV-monoinfected patients. We prospectively enrolled 502 viremic HCV patients with paired plasma samples (at intervals of ≥ 12 months) from 5 tertiary hospitals. Anti-HEV IgG positivity was tested using the Wantai ELISA kit in all paired samples. Mean age was 58.2 ± 11.5 years old, 48.2% were male, 29.9% of patients had liver cirrhosis, and 9.4% of patients were diagnosed with hepatocellular carcinoma (HCC). The overall prevalence of anti-HEV IgG positivity at enrollment was 33.3%, with a higher prevalence in males and increasing prevalence according to the subject's age. During the 916.4 person-year, the HEV incidence rate was 0.98/100 person-years (9/335, 2.7%). Hepatic decompensation or liver-related mortality was not observed. There were six seroreversion cases among 172 anti-HEV-positive patients (1.22/100 person-years). In conclusion, approximately one-third of the adult Korean chronic HCV patients were anti-HEV IgG positive. The HEV incidence rate was 1 in 100 persons per year, without adverse hepatic outcomes or mortality.
Identifiants
pubmed: 37604848
doi: 10.1038/s41598-023-39019-3
pii: 10.1038/s41598-023-39019-3
pmc: PMC10442446
doi:
Substances chimiques
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13632Informations de copyright
© 2023. Springer Nature Limited.
Références
Nimgaonkar, I., Ding, Q., Schwartz, R. E. & Ploss, A. Hepatitis E virus: Advances and challenges. Nat. Rev. Gastroenterol. Hepatol. 15, 96–110 (2018).
doi: 10.1038/nrgastro.2017.150
pubmed: 29162935
Reyes, G. R. et al. Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science 247, 1335–1339 (1990).
doi: 10.1126/science.2107574
pubmed: 2107574
Khuroo, M. S., Khuroo, M. S. & Khuroo, N. S. Hepatitis E: Discovery, global impact, control and cure. World J. Gastroenterol. 22, 7030–7045 (2016).
doi: 10.3748/wjg.v22.i31.7030
pubmed: 27610014
pmcid: 4988308
Zeng, D. Y. et al. Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990–2019. J. Hepatol. 75, 547–556 (2021).
doi: 10.1016/j.jhep.2021.04.035
pubmed: 33961940
Lai, J. C. et al. Chronic hepatitis B increases liver-related mortality of patients with acute hepatitis E: A territorywide cohort study from 2000 to 2016. Clin. Infect. Dis. 67, 1278–1284 (2018).
doi: 10.1093/cid/ciy234
pubmed: 30265321
Tseng, T. C. et al. HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis. J. Hepatol. 72, 1105–1111 (2020).
doi: 10.1016/j.jhep.2020.01.012
pubmed: 32006586
Samala, N. et al. Hepatitis E virus does not contribute to hepatic decompensation among patients with advanced chronic hepatitis C. Clin. Gastroenterol. Hepatol. 14, 896–902 (2016).
doi: 10.1016/j.cgh.2015.12.048
pubmed: 26820399
Yoon, Y. et al. Hepatitis E Virus (HEV) seroprevalence in the general population of the Republic of Korea in 2007–2009: A nationwide cross-sectional study. BMC Infect. Dis. 14, 517 (2014).
doi: 10.1186/1471-2334-14-517
pubmed: 25248488
pmcid: 4262127
World Health Organization. The Global Prevalence of Hepatitis E Virus Infection and Susceptibility: A Systematic Review. http://www.who.int/vaccines-documents/ (2010).
Meng, X. J. et al. Prevalence of antibodies to hepatitis E virus in veterinarians working with swine and in normal blood donors in the United States and other countries. J. Clin. Microbiol. 40, 117–122 (2002).
doi: 10.1128/JCM.40.1.117-122.2002
pubmed: 11773103
pmcid: 120098
Faber, M. S. et al. Hepatitis E virus seroprevalence among adults, Germany. Emerg. Infect. Dis. 18, 1654–1657 (2012).
doi: 10.3201/eid1810.111756
pubmed: 23018055
pmcid: 3471611
Schulz, M. et al. High prevalence of anti-hepatitis E virus antibodies in outpatients with chronic liver disease in a university medical center in Germany. Eur. J. Gastroenterol. Hepatol. 28, 1431–1436 (2016).
doi: 10.1097/MEG.0000000000000729
pubmed: 27552296
Dong, C., Dai, X., Shao, J. S., Hu, K. & Meng, J. H. Identification of genetic diversity of hepatitis E virus (HEV) and determination of the seroprevalence of HEV in eastern China. Arch. Virol. 152, 739–746 (2007).
doi: 10.1007/s00705-006-0882-0
pubmed: 17131064
Chiu, D. M., Chan, M. C., Yeung, A. C., Ngai, K. L. & Chan, P. K. Seroprevalence of hepatitis E virus in Hong Kong, 2008–2009. J. Med. Virol. 85, 459–461 (2013).
doi: 10.1002/jmv.23429
pubmed: 23239426
Pisano, M. B., Campbell, C., Anugwom, C., Re, V. E. & Debes, J. D. Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays. PLoS ONE 17, e0272809 (2022).
doi: 10.1371/journal.pone.0272809
pubmed: 35930611
pmcid: 9355204
Ijaz, S. et al. Indigenous hepatitis E virus infection in England: More common than it seems. J. Clin. Virol. 44, 272–276 (2009).
doi: 10.1016/j.jcv.2009.01.005
pubmed: 19217345
Wong, R. J., Cheung, R., Gish, R. G. & Chitnis, A. S. Prevalence of hepatitis E infection among adults with concurrent chronic liver disease. J. Viral Hepat. 28, 1643–1655 (2021).
doi: 10.1111/jvh.13597
pubmed: 34415657
Bayram, A., Eksi, F., Mehli, M. & Sozen, E. Prevalence of hepatitis E virus antibodies in patients with chronic hepatitis B and chronic hepatitis C. Intervirology 50, 281–286 (2007).
doi: 10.1159/000103916
pubmed: 17570930
Koning, L. et al. Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States. BMC Infect. Dis. 15, 371 (2015).
doi: 10.1186/s12879-015-1103-9
pubmed: 26328802
pmcid: 4557757
Yang, H., Wu, J., Yuan, Y., Huang, W. & Jia, B. Retrospectively seroprevalence study on anti-HEV-IgG antibody in patients with chronic hepatitis or liver cirrhosis in a Chinese teaching hospital. J. Med. Virol. 91, 437–443 (2019).
doi: 10.1002/jmv.25335
pubmed: 30307619
Huang, H. et al. Incidence and seroprevalence of hepatitis E virus infection in pregnant women infected with hepatitis B virus and antibody placental transfer in infants. J. Clin. Virol. 82, 84–88 (2016).
doi: 10.1016/j.jcv.2016.07.010
pubmed: 27467017
Juhl, D., Baylis, S. A., Blumel, J., Gorg, S. & Hennig, H. Seroprevalence and incidence of hepatitis E virus infection in German blood donors. Transfusion 54, 49–56 (2014).
doi: 10.1111/trf.12121
pubmed: 23441647
Choi, J. W. et al. Acute hepatitis E virus superinfection increases mortality in patients with cirrhosis. BMC Infect. Dis. 22, 62 (2022).
doi: 10.1186/s12879-022-07050-w
pubmed: 35042464
pmcid: 8767750
Hoan, N. X. et al. Hepatitis E virus superinfection and clinical progression in hepatitis B patients. EBioMedicine 2, 2080–2086 (2015).
doi: 10.1016/j.ebiom.2015.11.020
pubmed: 26844288
pmcid: 4703726
Burkard, T. et al. Viral interference of hepatitis C and E virus replication in novel experimental co-infection systems. Cells 11, 927 (2022).
doi: 10.3390/cells11060927
pubmed: 35326378
pmcid: 8946046
Sherman, K. E. et al. Hepatitis E infection in a longitudinal cohort of hepatitis C virus and HCV/HIV coinfected persons. AIDS Res. Hum. Retroviruses. 37, 534–541 (2021).
doi: 10.1089/aid.2020.0303
pubmed: 33794657
pmcid: 8260885
Cangin, C., Focht, B., Harris, R. & Strunk, J. A. Hepatitis E seroprevalence in the United States: Results for immunoglobulins IGG and IGM. J. Med. Virol. 91, 124–131 (2019).
doi: 10.1002/jmv.25299
pubmed: 30168589
Faber, M. et al. Hepatitis E virus seroprevalence, seroincidence and seroreversion in the German adult population. J. Viral Hepat. 25, 752–758 (2018).
doi: 10.1111/jvh.12868
pubmed: 29377436
Kulkarni, S. P., Sharma, M. & Tripathy, A. S. Antibody and memory B cell responses in hepatitis E recovered individuals, 1–30 years post hepatitis E virus infection. Sci. Rep. 9, 4090 (2019).
doi: 10.1038/s41598-019-40603-9
pubmed: 30858463
pmcid: 6411774
Brown, A. et al. Characterization of the specificity, functionality, and durability of host T-cell responses against the full-length hepatitis E virus. Hepatology 64, 1934–1950 (2016).
doi: 10.1002/hep.28819
pubmed: 27631819
Myint, K. S. et al. Hepatitis E antibody kinetics in Nepalese patients. Trans. R. Soc. Trop. Med. Hyg. 100, 938–941 (2006).
doi: 10.1016/j.trstmh.2005.12.005
pubmed: 16542692
Riveiro-Barciela, M. et al. Unexpected long-lasting anti-HEV IgM positivity: Is HEV antigen a better serological marker for hepatitis E infection diagnosis?. J. Viral Hepat. 27, 747–753 (2020).
doi: 10.1111/jvh.13285
pubmed: 32106351
Nam, J. Y. et al. Epidemiological and clinical characteristics of hepatitis C virus infection in South Korea from 2007 to 2017: A prospective multicenter cohort study. Gut Liver. 14, 207–217 (2020).
doi: 10.5009/gnl19005
pubmed: 31158950
Lin, Z. H. et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: An updated meta-analysis. Hepatology 53, 726–736 (2011).
doi: 10.1002/hep.24105
pubmed: 21319189
Kim, B. K. et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int. 30, 546–553 (2010).
doi: 10.1111/j.1478-3231.2009.02192.x
pubmed: 20074094